Press releases
Presentation at the International Society of NeuroVirology 2022 of top-line data of academic collaborations further documenting the long-term expression of the Proinflammatory and Neuropathogenic W-ENV protein in cohorts of post-COVID Patients
Geneva, Switzerland, October 17, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled new data further documenting the presence of W-ENV in cohorts of post-COVID patients at the18th Symposium of the International Society of Neuro Virology (ISNV) held on October 11-14, 2022.
https://geneuro.com/data/news/GeNeuro-ISNV-presentation-ENG-Oct.-17-2022.pdf
GeNeuro Reports 2022 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2022, at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today reported its half-year financial results for the period ending June 30, 2022 and provided a corporate update.
https://geneuro.ch/data/news/GeNeuro-PR-1H2022-Results-ENG.pdf
GeNeuro: financial information and business update for the second quarter 2022
Geneva, Switzerland, July 21, 2022, 5.45 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.
GeNeuro Announces Approval of all Resolutions Proposed at 2022 Annual General Meeting
Geneva, Switzerland, June 2, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 31, 2022.
GeNeuro is granted authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post COVID syndromes
Geneva, Switzerland, May 11, 2022– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announces today it has received the authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post-COVID syndromes.
https://geneuro.ch/data/news/GeNeuro-PR-05112022-Swissmedic-approval-ENG-VF2.pdf
GeNeuro publishes its 2021 Universal Registration Document
Geneva, Switzerland, April 27, 2022 – 6:00 pm CEST GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), publishes its 2021 Universal Registration Document, in English, which has been filed on April 27, 2022 with the “Autorité des Marchés Financiers (AMF)”.
https://geneuro.ch/data/news/GeNeuro-PR-Mise-a-dispo-URD-2021-EN.pdf